Anavex Life Sciences Announces Publication of Clinical Data for ANAVEX®2-73 (blarcamesine) in Alzheimer’s Disease

Anavex Life Sciences Announces Publication of Clinical Data for ANAVEX®2-73 (blarcamesine) in Alzheimer’s Disease Published in Alzheimer’s & Dementia Journal, Results Highlight ANAVEX®2-73 (blarcamesine) Clinical Study, the First Reported Genome-Wide Search for Biomarkers Associated with Drug Response in Alzheimer’s Disease Clinically Meaningful Biomarkers Identified in ANAVEX®2-73 (blarcamesine) Studies Demonstrate a Significant Impact on Clinical Outcomes…

Anavex Life Sciences to Webcast 2020 Annual Meeting of Shareholders

Anavex Life Sciences to Webcast 2020 Annual Meeting of Shareholders NEW YORK – March 23, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS)…

Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Disease Dementia (PDD) Clinical Trial

Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Disease Dementia (PDD) Clinical Trial   NEW YORK – January 27, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s…